Trials / Completed
CompletedNCT04450108
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
Clinical Study of the Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients Responding to Inhaled Corticosteroid (ICS) Treatment
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Bosch Healthcare Solutions GmbH · Industry
- Sex
- All
- Age
- 7 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.
Detailed description
Subjects will be screened, enrolled and tested at Study Visit #1 and then prescribed inhaled corticosteroid (ICS) treatment as per routine clinical care. Subjects will return for Study Visit #2 in two weeks and repeat fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Vivatmo pro FeNO Test | Breath gas analysis |
Timeline
- Start date
- 2020-09-08
- Primary completion
- 2020-12-18
- Completion
- 2021-04-13
- First posted
- 2020-06-29
- Last updated
- 2022-06-06
- Results posted
- 2022-06-06
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04450108. Inclusion in this directory is not an endorsement.